1
Ich is distinct from the wellcharacterized chromosomal instability pathway [15]. Patients with colorectal cancer containing a BRAF mutation or those with CIMP-positive tend to be older, smokers, women, right-sided, and have a higher-grade histology [16, 17]. In light of the aforementioned evidence and other findings that patients with BRAF-mutant and/or CIMP-positive colorectal cancer (particularl
1
E of patients with colorectal cancer and even other cancers harboring BRAF mutations. In this study, we aimed to identify miRNAs that are specifically dysregulated in BRAF-mutant colorectal cancer using a genome-wide miRNA expression analysis, and to clarify whether these miRNAs play a role in colorectal tumorigenesis as an oncogene or a tumor-suppressor through functional assays using colorectal
1
Tion into the brain through modifications to the actin cytoskeleton and the levels of expression of small GTPases. J Neuropathol Exp Neurol 2002, 61:585?97. Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius HJ, Kiss R: Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 2005, 335:27?5. Jung TY, Jung S, Ryu HH, Jeong YI, Jin
1
Mail: Vinzenz Link - link@mpi-cbg.de; Andrej Shevchenko - shevchenko@mpi-cbg.de; Carl-Philipp Heisenberg* - heisenberg@mpi-cbg.de * Corresponding authorPublished: 13 January 2006 BMC Developmental Biology 2006, 6:1 doi:10.1186/1471-213X-6-Received: 28 August 2005 Accepted: 13 JanuaryThis article is available from: http://www.biomedcentral.com/1471-213X/6/1 ?2006 Link et al; licensee BioMed Central
1
Man T lymphocytes. J Immunol 1998, 161:2114?119. 47. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cellmediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004, 5:241?51. 48. Kuppner MC, Hamou MF, Sawamura
1
Mail: Vinzenz Link - link@mpi-cbg.de; Andrej Shevchenko - shevchenko@mpi-cbg.de; Carl-Philipp Heisenberg* - heisenberg@mpi-cbg.de * Corresponding authorPublished: 13 January 2006 BMC Developmental Biology 2006, 6:1 doi:10.1186/1471-213X-6-Received: 28 August 2005 Accepted: 13 JanuaryThis article is available from: http://www.biomedcentral.com/1471-213X/6/1 ?2006 Link et al; licensee BioMed Central
1
Yolk removal. Embryos with yolk (Y) were analysed in comparison with embryos after one-step deyolking (D) or after two additional wash steps (W). A. Total protein amount per embryo as determined by DC protein assay (Bio-Rad). B. Coomassie stain (0.5 embryos loaded per lane). C. Western blot against Tubulin and MEK (0.5 embryos loaded per lane). While yolk proteins were efficiently depleted, recove
1
X Ethnicity (n = 555, 336, 219) White/Caucasian (reference) Unknown/Mixed/ Other Aboriginal Asian Obesity Diabetes mellitus Chronic obstructive pulmonary disease Alcohol abuse Chronic kidney disease Day 1 support, physiology, and laboratory values APACHE II score (n = 508, 306, 202) Invasive mechanical ventilation (n = 553, 338, 215) Inotrope or vasopressor Mean arterial pressure (mmHg) (n = 522,